Study Description
This is a Phase IIIb, multicenter, two-arm, randomized, double-blind, parallel group study to evaluate the efficacy and safety of zigakibart + atrasentan compared to zigakibart + placebo in patients with primary IgAN at risk of disease progression. The study includes a 52-week double-blind treatment period and a 52-week open-label extension (OLE):
* Double-blind treatment period: Participants will receive zigakibart and either atrasentan or matching placebo. The purpose is to evaluate if zigakibart + atrasentan demonstrates increased efficacy in reducing proteinuria and delaying progression of disease compared to zigakibart + placebo. It also aims to evaluate the safety and tolerability of zigakibart + atrasentan.
* OLE: Participants will receive zigakibart and atrasentan. The purpose is to provide study participants with the opportunity to continue to receive zigakibart and atrasentan, while enabling continued collection of long-term efficacy, safety, and tolerability data.
Interventions
atrasentan
Placebo
zigakibart
Eligibility Criteria
Inclusion Criteria:
* Aged ≥ 18 years at the time of signing the informed consent, prior to initiation of any study specific activities/procedures
* Biopsy-proven IgAN diagnosed within the past 10 years prior to Screening, that, in the opinion of the Investigator, is not due to secondary causes. If a biopsy report within 10 years is not available, re-biopsy may be performed locally during Screening.
* eGFR ≥ 30 mL/min/1.73m2 by a central laboratory at Screening, calculated using serum creatinine based on the 2021 CKD-EPI equation (Inker et al 2021)
* UPCR ≥ 0.7 g/g (700 mg/g), as measured from a 24 hour urine collection by a central laboratory at Screening
* Stable on a maximally tolerated dose of ACEi and/or ARB for at least 12 weeks prior to Screening unless intolerant to ACEi and ARB. May also be on a stable and well tolerated dose of SGLT2i, MRA, and/or GLP-1A if stable for at least 12 weeks prior to Screening. Participants are expected to stay on a stable dose of ACEi, ARB, SGLT2i, MRA and/or GLP-1A for the duration of the study.
Exclusion Criteria:
* Chronic Kidney Disease (CKD), either clinically suspected or based on biopsy, resulting from any condition or another glomerulopathy/podocytopathy other than IgAN
* Secondary forms of IgAN as determined by the Investigator, in the setting of systemic disorders, infections, autoimmune disorders or neoplasia
* Diagnosis of active IgA vasculitis
* Clinical suspicion of IgAN with rapidly progressive glomerulonephritis (RPGN) based on Kidney Disease: Improving Global Outcomes (KDIGO) guidelines (2025)
* Current clinical diagnosis of nephrotic syndrome
* Known history of heart failure or conditions relating to fluid overload such as pulmonary edema, uncontrolled peripheral edema, pleural effusion, or ascites
* Current severe infection requiring antimicrobials, or history of recurrent, severe infections as determined by the Investigator
Other protocol-defined inclusion/exclusion criteria may apply
Novartis Investigative Site
Recruiting
Nedlands,Western Australia,6009,Australia
Novartis Investigative Site
Recruiting
Petah Tikva,4941492,Israel
Novartis Investigative Site
Recruiting
Beersheba,8457108,Israel
Florida Kidney Physicians LLC
Recruiting
Temple Terrace,Florida,33637,United States
Wayne Robert Kotzker
Bianca Philippe
Northern Assoc of Northern VA
Recruiting
Fairfax,Virginia,22033,United States
Ahmadshah Mirkhel
DaVita Clinical Research
Recruiting
Las Vegas,Nevada,89146,United States
Mark Vishnepolsky
Farzana Siddiqui
Southeast Kidney Associates
Recruiting
East Point,Georgia,30344,United States
Charmaine Emelife
Nephrology Consultants LLC
Recruiting
Huntsville,Alabama,35805,United States
Michael Quadrini
Florida Kidney Physicians
Recruiting
Riverview,Florida,33578,United States
Myra Rodriguez
Amit Johnsingh
Nephrology Associates PA
Recruiting
Newark,Delaware,19713,United States
Theodore Saad
Nicole Davis
West Coast Kidney Institute
Recruiting
Fremont,California,94538,United States
Varun Chawla
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.